BACKGROUND: CD4 T cell depletion in the mucosa has been well documented during acute HIV and SIV infections. The demonstration the HIV/SIVcan use the alpha4beta7 receptor for viral entry suggests that these viruses selectively target CD4 T cells in the mucosa that express high levels of alpha4beta7 receptor. METHODS: Mucosal samples obtained from SIV infected rhesus macaques during the early phase of infection were used for immunophenotypic analysis. CD4 T cell subsets were sorted based on the expression of beta7 and CD95 to quantify the level of SIV infection in different subsets of CD4 T cells. Changes in IL-17, IL-21, IL-23 and TGFbeta mRNA expression was determined using Taqman PCR. RESULTS: CD4 T cells in the mucosa were found to harbor two major population of cells; -25% of CD4 T cells expressed the alpha4(+)beta7(hi) phenotype, whereas the rest of the 75% expressed an alpha4(+)beta7(int) phenotype. Both the subsets were predominantly CD28(+)Ki-67(-)HLA-DR(-) but CD69(+), and expressed detectable levels of CCR5 on their surface. Interestingly, however, alpha4(+)beta7(hi)CD4 T cells were found to harbor more SIV than the alpha4(+)beta7(int) subsets at day 10 pi. Early infection was associated with a dramatic increase in the expression of IL-17, and IL-17 promoting cytokines IL-21, IL-23, and TGFbeta that stayed high even after the loss of mucosal CD4 T cells. CONCLUSIONS: Our results suggest that the differential expression of the alpha4beta7 receptor contributes to the differences in the extent of infection in CD4 T cell subsets in the mucosa. Early infection is associated dysregulation of the IL-17 network in mucosal tissues involves other non-Th-17 cells that likely contributes to the pro-inflammatory environment in the mucosa during acute stages of SIV infection.
BACKGROUND:CD4 T cell depletion in the mucosa has been well documented during acute HIV and SIV infections. The demonstration the HIV/SIVcan use the alpha4beta7 receptor for viral entry suggests that these viruses selectively target CD4 T cells in the mucosa that express high levels of alpha4beta7 receptor. METHODS: Mucosal samples obtained from SIV infectedrhesus macaques during the early phase of infection were used for immunophenotypic analysis. CD4 T cell subsets were sorted based on the expression of beta7 and CD95 to quantify the level of SIV infection in different subsets of CD4 T cells. Changes in IL-17, IL-21, IL-23 and TGFbeta mRNA expression was determined using Taqman PCR. RESULTS:CD4 T cells in the mucosa were found to harbor two major population of cells; -25% of CD4 T cells expressed the alpha4(+)beta7(hi) phenotype, whereas the rest of the 75% expressed an alpha4(+)beta7(int) phenotype. Both the subsets were predominantly CD28(+)Ki-67(-)HLA-DR(-) but CD69(+), and expressed detectable levels of CCR5 on their surface. Interestingly, however, alpha4(+)beta7(hi)CD4 T cells were found to harbor more SIV than the alpha4(+)beta7(int) subsets at day 10 pi. Early infection was associated with a dramatic increase in the expression of IL-17, and IL-17 promoting cytokines IL-21, IL-23, and TGFbeta that stayed high even after the loss of mucosal CD4 T cells. CONCLUSIONS: Our results suggest that the differential expression of the alpha4beta7 receptor contributes to the differences in the extent of infection in CD4 T cell subsets in the mucosa. Early infection is associated dysregulation of the IL-17 network in mucosal tissues involves other non-Th-17 cells that likely contributes to the pro-inflammatory environment in the mucosa during acute stages of SIV infection.
Authors: Christine J Pitcher; Shoko I Hagen; Joshua M Walker; Richard Lum; Bridget L Mitchell; Vernon C Maino; Michael K Axthelm; Louis J Picker Journal: J Immunol Date: 2002-01-01 Impact factor: 5.422
Authors: Daniel C Douek; Jason M Brenchley; Michael R Betts; David R Ambrozak; Brenna J Hill; Yukari Okamoto; Joseph P Casazza; Janaki Kuruppu; Kevin Kunstman; Steven Wolinsky; Zvi Grossman; Mark Dybul; Annette Oxenius; David A Price; Mark Connors; Richard A Koup Journal: Nature Date: 2002-05-02 Impact factor: 49.962
Authors: R S Veazey; M DeMaria; L V Chalifoux; D E Shvetz; D R Pauley; H L Knight; M Rosenzweig; R P Johnson; R C Desrosiers; A A Lackner Journal: Science Date: 1998-04-17 Impact factor: 47.728
Authors: J D Lifson; J L Rossio; M Piatak; T Parks; L Li; R Kiser; V Coalter; B Fisher; B M Flynn; S Czajak; V M Hirsch; K A Reimann; J E Schmitz; J Ghrayeb; N Bischofberger; M A Nowak; R C Desrosiers; D Wodarz Journal: J Virol Date: 2001-11 Impact factor: 5.103
Authors: A I Lazarovits; R A Moscicki; J T Kurnick; D Camerini; A K Bhan; L G Baird; M Erikson; R B Colvin Journal: J Immunol Date: 1984-10 Impact factor: 5.422
Authors: Saurabh Mehandru; Michael A Poles; Klara Tenner-Racz; Amir Horowitz; Arlene Hurley; Christine Hogan; Daniel Boden; Paul Racz; Martin Markowitz Journal: J Exp Med Date: 2004-09-13 Impact factor: 14.307
Authors: Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek Journal: J Exp Med Date: 2004-09-13 Impact factor: 14.307
Authors: Stephanie M Dillon; Jennifer A Manuzak; Amanda K Leone; Eric J Lee; Lisa M Rogers; Martin D McCarter; Cara C Wilson Journal: J Immunol Date: 2012-06-11 Impact factor: 5.422
Authors: Mangala Rao; Kristina K Peachman; Jiae Kim; Guofen Gao; Carl R Alving; Nelson L Michael; Venigalla B Rao Journal: Curr HIV Res Date: 2013-07 Impact factor: 1.581